Friday 16 October 2026
Export CUE’s income statement to Excel — free account
Cue Biopharma, Inc.
Cue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024. In the quarter to June 2026, revenue grew 166.7%, EPS fell 793.2% and free cash flow fell 742.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
16.96
1.71
−9.16%
Follow CUE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.31 | 1.01 | 1.05 | 10.20 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.90) | (3.03) | (26.83) | (8.03) | |
P/B ratio |
86.63 | 1.54 | 1.09 | 5.47 | |
Price to Tangible BV |
93.73 | 1.55 | 1.10 | 5.54 | |
EV/Sales |
4.90 | 0.53 | 0.08 | 7.56 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.68) | (0.71) | (0.11) | (1.81) | |
EV/FCF |
(3.68) | (0.71) | (0.10) | (1.80) | |
Quick Ratio |
1.07 | 3.08 | 2.50 | 1.34 | |
Current Ratio |
1.25 | 3.57 | 2.74 | 1.66 | |
Net Debt/EBITDA |
0.20 | 3.64 | (10.72) | 2.44 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 5.21% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.12 | |
Asset Turnover |
1.05 | 1.23 | 0.74 | 0.19 | |
Operating CF/Net income |
0.19 | 2.11 | (0.68) | 1.21 | |
Capex/Depreciation |
0.00 | (0.21) | 0.03 | (0.22) | |
Interest Coverage |
(17,539.00) | (1,338.25) | 18.14 | (101.27) | |
Research and Development Expense of Revenue |
622.15% | 121.30% | 75.34% | 221.22% | |
Selling, General and Administrative Expense of Revenue |
591.15% | 73.02% | 15.74% | 229.83% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
302.63% | 0.84% | 2.78% | 71.34% | |
Graham Net Nets |
(0.01) | 0.52 | 0.73 | 0.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(85.62%) | (80.93%) | (105.02%) | (64.04%) | |
Free Cash Flow Yield |
(25.05%) | (74.05%) | (75.61%) | (41.13%) | |
Revenue per Share |
1.24 | 1.18 | 6.96 | 0.64 | |
Operating CF per Share |
(4.57) | (2.28) | (0.34) | (2.69) | |
Capex per Share |
0.00 | (0.03) | 0.01 | 0.01 | |
Free Cash Flow per Share |
(4.57) | (2.30) | (0.33) | (2.68) | |
Cash per Share |
2.75 | 3.63 | 8.95 | 6.08 | |
Shareholders Equity per Share |
0.36 | 4.49 | 8.38 | 3.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.36 | 4.49 | 8.38 | 3.94 | |
Free Cash Flow |
(29.00) | (11.06) | (1.06) | (9.00) | |
Working Capital |
5.41 | 19.00 | 23.49 | 10.30 | |
Capital Expenditures |
0.00 | (0.12) | 0.02 | 0.02 | |
Net Current Asset Value |
(1.77) | 17.12 | 21.20 | 7.42 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.02 | 0.00 | (0.01) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.95 | 3.15 | 4.35 | 1.12 | |
Average Payables |
3.69 | 3.56 | 3.39 | 4.41 | |
Average Assets |
35.71 | 26.57 | 37.20 | 38.23 | |
Average Common Equity |
10.23 | 14.09 | 21.97 | 19.31 |
Columns are period end dates